Industry
OpenAI partners with Novo Nordisk to accelerate drug discovery and delivery
Artificial intelligence powerhouse OpenAI Group PBC is lending its expertise to Novo Nordisk A/S in a new partnership announced today that aims to accelerate research in the pharmaceutical industry. T
Artificial intelligence powerhouse OpenAI Group PBC is lending its expertise to Novo Nordisk A/S in a new partnership announced today that aims to accelerate research in the pharmaceutical industry. The sweeping collaboration will see OpenAI’s intelligent agents embedded across the drug maker’s workflows in order to enhance everything from lab-based drug discovery to the complexities […] The post OpenAI partners with Novo Nordisk to accelerate drug discovery and delivery appeared first on SiliconANGLE.
Related
- Powering clinical research innovation: How TriNetX uses Databricks to accelerate drug development
- Amazon CEO Andy Jassy highlights AI growth in annual shareholder letter
- Meta says it will spend an additional $21B on CoreWeave’s AI infrastructure
- OpenAI plans to open its first permanent London office with a 500+ staff capacity; in February, OpenAI said it would make London its largest non-US research hub (Kai Nicol-Schwarz/CNBC)
Source: SiliconANGLE | 2026-04-14